202 related articles for article (PubMed ID: 22811299)
1. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.
Roy U; McMillan J; Alnouti Y; Gautum N; Smith N; Balkundi S; Dash P; Gorantla S; Martinez-Skinner A; Meza J; Kanmogne G; Swindells S; Cohen SM; Mosley RL; Poluektova L; Gendelman HE
J Infect Dis; 2012 Nov; 206(10):1577-88. PubMed ID: 22811299
[TBL] [Abstract][Full Text] [Related]
2. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.
Dash PK; Gendelman HE; Roy U; Balkundi S; Alnouti Y; Mosley RL; Gelbard HA; McMillan J; Gorantla S; Poluektova LY
AIDS; 2012 Nov; 26(17):2135-44. PubMed ID: 22824628
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.
Puligujja P; Balkundi SS; Kendrick LM; Baldridge HM; Hilaire JR; Bade AN; Dash PK; Zhang G; Poluektova LY; Gorantla S; Liu XM; Ying T; Feng Y; Wang Y; Dimitrov DS; McMillan JM; Gendelman HE
Biomaterials; 2015 Feb; 41():141-50. PubMed ID: 25522973
[TBL] [Abstract][Full Text] [Related]
4. Suppression of Active HIV-1 Infection in CD34
Latinovic OS; Neal LM; Tagaya Y; Heredia A; Medina-Moreno S; Zapata JC; Reitz M; Bryant J; Redfield RR
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):718-728. PubMed ID: 31099257
[TBL] [Abstract][Full Text] [Related]
5. Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Kanmogne GD; Singh S; Roy U; Liu X; McMillan J; Gorantla S; Balkundi S; Smith N; Alnouti Y; Gautam N; Zhou Y; Poluektova L; Kabanov A; Bronich T; Gendelman HE
Int J Nanomedicine; 2012; 7():2373-88. PubMed ID: 22661891
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Puligujja P; Araínga M; Dash P; Palandri D; Mosley RL; Gorantla S; Poluektova L; McMillan J; Gendelman HE
Antiviral Res; 2015 Aug; 120():85-8. PubMed ID: 26026666
[TBL] [Abstract][Full Text] [Related]
7. The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.
Zhang G; Guo D; Dash PK; Araínga M; Wiederin JL; Haverland NA; Knibbe-Hollinger J; Martinez-Skinner A; Ciborowski P; Goodfellow VS; Wysocki TA; Wysocki BJ; Poluektova LY; Liu XM; McMillan JM; Gorantla S; Gelbard HA; Gendelman HE
Nanomedicine; 2016 Jan; 12(1):109-22. PubMed ID: 26472049
[TBL] [Abstract][Full Text] [Related]
8. Long-acting slow effective release antiretroviral therapy.
Edagwa B; McMillan J; Sillman B; Gendelman HE
Expert Opin Drug Deliv; 2017 Nov; 14(11):1281-1291. PubMed ID: 28128004
[TBL] [Abstract][Full Text] [Related]
9. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.
Guo D; Zhang G; Wysocki TA; Wysocki BJ; Gelbard HA; Liu XM; McMillan JM; Gendelman HE
J Virol; 2014 Sep; 88(17):9504-13. PubMed ID: 24920821
[TBL] [Abstract][Full Text] [Related]
10. A Simple Mouse Model for the Study of Human Immunodeficiency Virus.
Kim KC; Choi BS; Kim KC; Park KH; Lee HJ; Cho YK; Kim SI; Kim SS; Oh YK; Kim YB
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):194-202. PubMed ID: 26564392
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses.
Watanabe S; Terashima K; Ohta S; Horibata S; Yajima M; Shiozawa Y; Dewan MZ; Yu Z; Ito M; Morio T; Shimizu N; Honda M; Yamamoto N
Blood; 2007 Jan; 109(1):212-8. PubMed ID: 16954502
[TBL] [Abstract][Full Text] [Related]
13. UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Huang J; Gautam N; Bathena SP; Roy U; McMillan J; Gendelman HE; Alnouti Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(23):2332-8. PubMed ID: 21752731
[TBL] [Abstract][Full Text] [Related]
14. The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture.
Gendelman HE; McMillan J; Bade AN; Edagwa B; Kevadiya BD
Trends Microbiol; 2019 Jul; 27(7):593-606. PubMed ID: 30981593
[TBL] [Abstract][Full Text] [Related]
15. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
16. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
17. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
18. Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Perazzolo S; Shireman LM; Koehn J; McConnachie LA; Kraft JC; Shen DD; Ho RJY
J Pharm Sci; 2018 Dec; 107(12):3153-3162. PubMed ID: 30121315
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
20. Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.
Tran TA; Ghosn J; Avettand-Fenoël V; Hendel-Chavez H; de Goër de Herve MG; Cohen-Codar I; Rouzioux C; Delfraissy JF; Taoufik Y
J Antimicrob Chemother; 2015 Sep; 70(9):2627-31. PubMed ID: 26023212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
